Join the Oncology Voice Network. Join for Free
How Cross-Functional Teams Reshape Cancer Care
Jay Fine Preclinical Research Early Stage

How Cross-Functional Teams Reshape Cancer Care


Share This Article


Summary

In episode 3 of Oncology Voice Network Podcast, Dr. Kirk Shepard sits down with Dr. Jay Fine, a renowned immunologist and President of R&D at Evolve Immune Therapeutics and a Forbes-published author in Voices of Oncology, for a candid look at how discovery truly connects to patient care.

How does real innovation in cancer therapy begin? Step into the world of preclinical drug discovery, where every molecule—and every lesson—matters.

In this episode of Oncology Voice Network Podcast, Host Dr. Kirk Shepard sits down with Dr. Jay Fine, a renowned immunologist and President of R&D at Evolve Immune Therapeutics and a Forbes-published author in Voices of Oncology, for a candid look at how discovery truly connects to patient care.

Together, they explore how personal stories, cross-functional teamwork, and the willingness to share both successes and failures can reshape outcomes for cancer patients.

Dr. Fine reflects on the human inspiration behind his decades of work, breaks the myth of the lone scientist by emphasizing the power of collaboration, and explains how preclinical data guides every step of a therapy’s path to patients. He also emphasizes the importance of open partnerships among pharma, biotech, payers, and patient advocates. Looking ahead, they discuss big ideas shaping the future, from data sharing and adaptive trials to more patient-centered strategies.

Discover why a new era of shared innovation is essential to accelerating breakthroughs and ensuring no patient is left behind. Tune in now.

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Leveraging existing data to contextualize phase II clinical trial findings in oncology
OVN Avatar E.M. Ray, L.A. Carey, K.E. Reeder-Hayes

Leveraging existing data to contextualize phase II clinical trial findings in oncology

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
OVN Avatar Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

Explore OVN